<p>Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic <em>EGFR</em>-Mutant NSCLC Patients: Efficacy, Acquired Resistance and Perspectives for Subsequent Treatments</p>-Reference-Cited by-同舟云学术

Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic EGFR-Mutant NSCLC Patients: Efficacy, Acquired Resistance and Perspectives for Subsequent Treatments

Published:2020-12 Issue: Volume:Volume 12 Page:12593-12602
ISSN:1179-1322
Container-title:Cancer Management and Research
language:en
Short-container-title:CMAR

Author:

Denis Marc G,Bennouna Jaafar^ORCID

Publisher

Informa UK Limited

Subject

Oncology

Reference73 articles.

1. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS

2. Correction to: “Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”

3. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

4. EGFR mutation-positive NSCLC: factors to consider when deciding first-line therapy

5. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structural Perspectives in the Development of Novel EGFR Inhibitors for the Treatment of NSCLC;Mini-Reviews in Medicinal Chemistry;2024-10

2. MET Oncogene Targeting for Cancer Immunotherapy;International Journal of Molecular Sciences;2024-06-01

3. Thromboembolic Events Associated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Pharmacovigilance Analysis of the US FDA Adverse Event Reporting System (FAERS) Database;Clinical Drug Investigation;2024-02-20

4. Phosphorylation of AGO2 by TBK1 Promotes the Formation of Oncogenic miRISC in NSCLC;Advanced Science;2024-02-13

5. Unveiling Potential Targeted Therapeutic Opportunities for Co-Overexpressed Targeting Protein for Xklp2 and Aurora-A Kinase in Lung Adenocarcinoma;Molecular Biotechnology;2023-09-28